Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
June 19, 2025
-
BUSINESS Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
June 18, 2025
-
ORGANIZATION JMA’s Upper House Candidate Says Scraping Drug Prices to Pool Resources No Longer Holds
June 17, 2025
-
REGULATORY Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
-
ORGANIZATION Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
-
BUSINESS AbbVie Japan Looks to Double Sales by 2029 with Rinvoq and Skyrizi as Engines
June 12, 2025
-
BUSINESS Prashant Nikam to Take Over Helm of MSD Japan
June 12, 2025
-
BUSINESS Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
-
BUSINESS Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
-
REGULATORY LDP Lawmakers Push Back on Honebuto Draft over CEA, Social Security Budgeting
June 10, 2025
-
REGULATORY Honebuto Draft Urges Promotion of Drug Innovation, but Spells Out CEA Expansion Too
June 9, 2025
-
BUSINESS Takeda Rolls Out AI Tool to Guide “Next Best Action” in Sales
June 6, 2025
-
ORGANIZATION New FPMAJ Chair Pushes Category-Based Drug Pricing to Ensure Innovation, Stable Supply
June 5, 2025
-
REGULATORY Early Honebuto Draft Contains CEA Expansion, Ramp-Up of FIH Trial Sites
June 4, 2025
-
ORGANIZATION New JPMA Chief Calls for Clear-Cut Evaluation of Innovation in FY2026 Reform
June 3, 2025
-
REGULATORY New Skipper of PMDA’s Review Center Wears Multiple Hats to Push Fight against Drug Loss
June 2, 2025
-
BUSINESS Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
-
BUSINESS Towa, Sawai Log Two-Digit Growth in Operating Profit, but Industry Sees Divide: Tally
May 30, 2025
-
BUSINESS Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
May 29, 2025
-
REGULATORY LDP Pharma Study Group’s Final Proposal Urges Raising of Social Security Budget Ceiling
May 29, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…